284 filings
Page 3 of 15
424B5
AFMD
Affimed N.V.
12 Apr 22
Prospectus supplement for primary offering
4:11pm
6-K
AFMD
Affimed N.V.
11 Apr 22
Affimed Presents Findings from the Dose-escalation Phase of the First-in-human
6:32am
EFFECT
AFMD
Affimed N.V.
7 Apr 22
Notice of effectiveness
12:15am
POS AM
AFMD
Affimed N.V.
31 Mar 22
Prospectus update (post-effective amendment)
4:37pm
20-F
2021 FY
AFMD
Affimed N.V.
Annual report (foreign)
31 Mar 22
8:59am
6-K
AFMD
Affimed N.V.
31 Mar 22
Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress
7:17am
POSASR
AFMD
Affimed N.V.
31 Mar 22
Automatic shelf registration (post-effective amendment)
7:10am
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 22
Affimed / Point72 Asset Management ownership change
4:34pm
SC 13G/A
AFMD
Affimed N.V.
14 Feb 22
Affimed / Ridgeback Capital Investments ownership change
12:00am
SC 13G/A
AFMD
Affimed N.V.
7 Feb 22
Affimed / BlackRock ownership change
4:40pm
SC 13G
683 Capital Management, LLC
7 Feb 22
Affimed / 683 Capital Management ownership change
4:25pm
6-K
AFMD
Affimed N.V.
6 Jan 22
Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022
7:23am
6-K
AFMD
Affimed N.V.
9 Dec 21
Current report (foreign)
7:30am
6-K
AFMD
Affimed N.V.
22 Nov 21
Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate
7:55am
6-K
AFMD
Affimed N.V.
10 Nov 21
Current report (foreign)
8:12am
F-3ASR
AFMD
Affimed N.V.
10 Nov 21
Automatic shelf registration (foreign)
7:48am
6-K
AFMD
Affimed N.V.
8 Sep 21
Unaudited Condensed Interim Consolidated Financial Statements
7:58am
6-K
AFMD
Affimed N.V.
1 Jul 21
Current report (foreign)
6:50am
6-K
AFMD
Affimed N.V.
16 Jun 21
Current report (foreign)
4:03pm
6-K
AFMD
Affimed N.V.
20 May 21
Affimed Announces Virtual Annual General Meeting of Shareholders
4:57pm